Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
December 11, 2023 08:30 ET
|
Mustang Bio, Inc.
Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma 100% of patients with...
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
November 02, 2023 09:28 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
November 03, 2022 09:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
December 13, 2021 09:00 ET
|
Mustang Bio, Inc.
95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of...
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
November 04, 2021 09:24 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
December 08, 2020 07:00 ET
|
uniQure Inc.
~ First primary endpoint in study met with mean Factor IX activity of 37% of normal at 26 weeks ~ ~ Data show 91% reduction in reported bleeds requiring treatment, with 87% of patients reporting no...
uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
December 07, 2020 16:05 ET
|
uniQure Inc.
~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Long-term Clinical Benefit and...
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
December 07, 2020 07:30 ET
|
Mustang Bio, Inc.
Data presented at the 62nd American Society of Hematology (ASH) Annual Meetingshow extremely favorable safety profile and clinical activity 89% overall response rate and 44% complete response rate in...
uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
November 30, 2020 07:05 ET
|
uniQure Inc.
~ Strong Presence at ASH Featuring Five Presentations, Including Late-BreakingOral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday, December 8, 2020 at 5:00 p.m. ET...